|
Originally published In Press as doi:10.1194/jlr.R300016-JLR200 on December 1, 2003
Journal of Lipid Research, Vol. 45, 205-213, February 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology
Phospholipase A2 in the central nervous system
:
implications for neurodegenerative diseases
Grace Y. Sun2,
Jianfeng Xu1,
Michael D. Jensen and
Agnes Simonyi
Department of Biochemistry, University of Missouri, Columbia, MO 65211
2 To whom correspondence should be addressed. e-mail: sung{at}health.missouri.edu
Phospholipase A2 (PLA2) belongs to a family of enzymes that catalyze the cleavage of fatty acids from the sn-2 position of phospholipids. There are more than 19 different isoforms of PLA2 in the mammalian system, but recent studies have focused on three major groups, namely, the group IV cytosolic PLA2, the group II secretory PLA2 (sPLA2), and the group VI Ca2+-independent PLA2. These PLA2s are involved in a complex network of signaling pathways that link receptor agonists, oxidative agents, and proinflammatory cytokines to the release of arachidonic acid (AA) and the synthesis of eicosanoids. PLA2s acting on membrane phospholipids have been implicated in intracellular membrane trafficking, differentiation, proliferation, and apoptotic processes. All major groups of PLA2 are present in the central nervous system (CNS). Therefore, this review is focused on PLA2 and AA release in neural cells, especially in astrocytes and neurons. In addition, because many neurodegenerative diseases are associated with increased oxidative and inflammatory responses, an attempt was made to include studies on PLA2 in cerebral ischemia, Alzheimer's disease, and neuronal injury due to excitotoxic agents.
Information from these studies has provided clear evidence for the important role of PLA2 in regulating physiological and pathological functions in the CNS.
Abbreviations: AA, arachidonic acid; AD, Alzheimer's disease; COX, cyclooxygenase; cPLA2, cytosolic PLA2; DHA, docosahexaenoic acid; ERK, extracellular signal-regulated protein kinase; FFA, free fatty acid; IFN , interferon gamma; IL-1ß, interleukin-1ß; iPLA2, Ca2+-independent PLA2; KA, kainic acid; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; MCA, middle cerebral artery; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NMDA, N-methyl-D-aspartic acid; PE, phosphatidylethanolamine; PEpl, ethanolamine plasmalogen; PGE2, prostaglandin E2; PLA2, phospholipase A2; ROS, reactive oxygen species; sPLA2, secretory PLA2; TNF , tumor necrosis factor alpha Supplementary key words astrocytes neurons neurodegeneration Alzheimer's disease cerebral ischemia

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. G. Bazan
Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease
J. Lipid Res.,
April 1, 2009;
50(Supplement):
S400 - S405.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. J. Lukiw and N. G. Bazan
Docosahexaenoic Acid and the Aging Brain
J. Nutr.,
December 1, 2008;
138(12):
2510 - 2514.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. G. Bazan
Homeostatic Regulation of Photoreceptor Cell Integrity: Significance of the Potent Mediator Neuroprotectin D1 Biosynthesized from Docosahexaenoic Acid The Proctor Lecture
Invest. Ophthalmol. Vis. Sci.,
November 1, 2007;
48(11):
4866 - 4881.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Takajo, K. Tsuchida, T. Murahashi, K. Ueno, and I. Koshiishi
Intramolecular rearrangement of linolenate peroxyl radicals in lipoxygenase reactions at lower oxygen content
J. Lipid Res.,
April 1, 2007;
48(4):
855 - 862.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Zhu, Y. Lai, P. B. Shelat, C. Hu, G. Y. Sun, and J. C-M. Lee
Phospholipases A2 Mediate Amyloid-beta Peptide-Induced Mitochondrial Dysfunction
J. Neurosci.,
October 25, 2006;
26(43):
11111 - 11119.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Farooqui, W.-Y. Ong, and L. A. Horrocks
Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders
Pharmacol. Rev.,
September 1, 2006;
58(3):
591 - 620.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Farooqui and L. A. Horrocks
Phospholipase A2-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly
Neuroscientist,
June 1, 2006;
12(3):
245 - 260.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Alloisio, R. Aiello, S. Ferroni, and M. Nobile
Potentiation of Native and Recombinant P2X7-Mediated Calcium Signaling by Arachidonic Acid in Cultured Cortical Astrocytes and Human Embryonic Kidney 293 Cells
Mol. Pharmacol.,
June 1, 2006;
69(6):
1975 - 1983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Sang, J. Zhang, V. Marcheselli, N. G. Bazan, and C. Chen
Postsynaptically Synthesized Prostaglandin E2 (PGE2) Modulates Hippocampal Synaptic Transmission via a Presynaptic PGE2 EP2 Receptor
J. Neurosci.,
October 26, 2005;
25(43):
9858 - 9870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Perez, R. Melero, M. A. Balboa, and J. Balsinde
Role of Group VIA Calcium-independent Phospholipase A2 in Arachidonic Acid Release, Phospholipid Fatty Acid Incorporation, and Apoptosis in U937 Cells Responding to Hydrogen Peroxide
J. Biol. Chem.,
September 24, 2004;
279(39):
40385 - 40391.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|